Here's a question that might not keep you up at night, but it's been on the minds of plenty of folks in the healthcare world: do expensive weight-loss drugs actually pay for themselves in the long run? A new real-world study suggests that for older adults, the answer is increasingly looking like yes.
The study, published in Diabetes, Obesity and Metabolism, focused on adults over 55 who are using Eli Lilly and Co. (LLY)'s Zepbound (tirzepatide) for weight management. It's the first to zero in on this specific age group, which includes people enrolled in the Medicare GLP-1 Bridge program. And the findings are pretty encouraging: sustained use of the drug is linked to fewer hospital admissions and emergency room visits, which translates into real money saved.
Meaningful Cost Savings Emerge Over Time
Researchers used two distinct analytical methods to estimate the financial differences, and they were careful to exclude the direct cost of the medication itself. Both approaches came to the same conclusion: patients taking Zepbound maintain lower monthly medical bills on average compared to those who aren't treated.
After six months of treatment, medical costs dropped by up to 15%, which works out to savings of as much as $181 per patient each month. But the real magic happens at the 12-month mark. By then, the financial gap had widened considerably, with patients seeing an estimated cost reduction of up to $607 monthly. That's a 38% decrease in expenses compared to those not receiving treatment.
The alternative analytical method told a similar story, showing a 12% cost reduction at six months and a 25% reduction at 12 months. So no matter how you slice the data, the trend is clear: the longer you stay on Zepbound, the more you save on other healthcare costs.
Offsetting Treatment Expenses
What's driving these savings? Adults using the treatment registered fewer emergency visits and hospitalizations across all observation periods. On the flip side, they showed higher rates of routine office visits, which suggests they're engaging more with preventive medical care. That's a good sign, both for their health and for the healthcare system's bottom line.
Here's where it gets interesting from a financial perspective. By six months, the estimated savings nearly offset the $195 monthly cost of the Medicare GLP-1 Bridge program. And once you hit one year of sustained treatment, the reduction in medical expenses actually surpassed the cost of Zepbound itself. That's a big deal, because it means long-term use in older populations can generate substantial financial benefits, not just health benefits.
Of course, this is a real-world study, not a randomized controlled trial, so it's worth taking with a grain of salt. But the findings align with what we're seeing in other research on GLP-1 drugs, and they add to the growing evidence that these medications might be more cost-effective than their sticker prices suggest.
As for Eli Lilly's stock, it was down 2.95% at $1197.23 at the time of publication on Wednesday, according to market data. Investors might be reacting to a variety of factors, but the long-term story here seems to be about the value these drugs can bring, both to patients and to the healthcare system.
So, is Zepbound worth it? For older adults who stick with it, the data suggests that the savings on hospital visits and other medical costs can eventually outweigh the price of the drug itself. That's a compelling argument, and it's one that's likely to shape the conversation around GLP-1 therapies for years to come.
